Ivonescimab's FDA Bet: Novel Dual Mechanism, Fragile Evidence Base, High Regulatory Stakes

FDA to Decide on Ivonescimab for EGFR-Mutated Lung Cancer

Summit Therapeutics and Akeso's ivonescimab is awaiting an FDA decision by November 14, 2026, for non-small cell lung cancer (NSCLC) with an EGFR mutation that has progressed after targeted therapy. The drug, a dual PD-1 and VEGF inhibitor, garnered attention after outperforming Keytruda in a China-based study in 2024. However, its U.S. submission faces scrutiny due to an initial lack of clear survival benefit in the primary analysis and reliance on exploratory data, raising questions about its approval prospects given the FDA's recent focus on robust evidence.

• The FDA's decision on ivonescimab is complicated by the initial primary analysis of the pivotal trial, which did not clearly demonstrate an extension of lives. While later, exploratory analyses suggested a "vaccinal effect," the agency has historically scrutinized submissions heavily reliant on such data, especially with minimal non-Chinese patient contribution to tumor progression measures.
• Ivonescimab is a first-of-its-kind cancer immunotherapy targeting both PD-1 and VEGF proteins, a novel approach that has sparked significant investment in similar dual-targeting drugs. Its potential to upend lung cancer care, similar to Keytruda's impact, is a subject of intense debate, with global trials ongoing and multiple competitors developing rival therapies.
• The current U.S. submission targets a specific patient population: individuals with EGFR-mutated lung cancer whose disease has progressed after prior targeted therapy. This positions ivonescimab in a competitive landscape where established therapies and other emerging dual-targeting agents are also being tested, making its differentiation and regulatory pathway critical for market penetration.

Ivonescimab's Pivotal Data Under FDA Scrutiny

Several recent studies have examined novel therapeutic strategies in EGFR-mutated NSCLC across resistance settings. The ORCHARD study (NCT03944772), a phase 2 platform trial, evaluated durvalumab plus etoposide-platinum in 14 patients with EGFR-mutated advanced NSCLC who developed neuroendocrine transformation following first-line osimertinib. The confirmed objective response rate (ORR) was 43% (80% CI: 24–63), with a median duration of response of 4.3 months (95% CI: 3.0–not calculable) and median progression-free survival (PFS) of 4.2 months (95% CI: 3.0–5.6). Median overall survival (OS) was 10.2 months (95% CI: 4.3–16.8). Grade ≥3 adverse events (AEs) were reported in 64% of patients, most commonly neutropenia and decreased neutrophil count (four patients each), with no new safety signals identified. Separately, the JVDL study (NCT02789345), a phase I trial, assessed ramucirumab plus osimertinib in 25 patients with T790M-positive EGFR-mutant NSCLC who had progressed on a prior EGFR TKI. The ORR was 76%, with a median duration of response of 13.4 months (90% CI: 9.6–21.2) and median PFS of 11.0 months (90% CI: 5.5–19.3). Efficacy was observed regardless of CNS metastasis status. The most common grade ≥3 treatment-related AEs were decreased platelet count (16%) and hypertension (8%); one grade 5 event (subdural hemorrhage) was reported.

A real-world multicenter study evaluated lazertinib, a third-generation EGFR TKI, in 103 patients with T790M-mutated NSCLC previously treated with an EGFR TKI. Among the 90 patients receiving lazertinib as second- or third-line therapy, the ORR was 62.1% and the disease control rate (DCR) was 94.2%. Median PFS was 13.9 months (95% CI: 11.0–not reached). In a subgroup of 33 patients with evaluable brain metastases, the intracranial DCR and ORR were 93.5% and 57.6%, respectively, with a median intracranial PFS of 17.1 months (95% CI: 13.9–not reached). Approximately 17.5% of patients required dose modification or discontinuation due to AEs, with grade 1 or 2 paresthesia being the most common. A real-world analysis of osimertinib-related cardiotoxicity across 1,126 patients treated between May 2016 and April 2023 identified an overall cardiotoxicity incidence of 4.7%, including 3.4% for osimertinib-related cardiac dysfunction requiring cardiologic intervention. Independent risk factors included advanced age, history of heart failure, atrial fibrillation, and baseline low left ventricular strain. The recovery rate of osimertinib-related cardiac dysfunction was 82.4%, which did not differ between patients who discontinued medication and those who did not.

A Bayesian network meta-analysis incorporating 19 randomized controlled trials and 4,039 participants assessed therapeutic options for EGFR-TKI-resistant NSCLC. Sacituzumab tirumotecan (Sac-TMT) demonstrated the most favorable efficacy profile, with a PFS hazard ratio of 0.20 (95% credible interval [CI]: 0.13–0.30) and an OS hazard ratio of 0.36 (95% CI: 0.20–0.66) versus conventional chemotherapy, supported by SUCRA values of 0.997 for PFS and 0.946 for OS. Datopotamab deruxtecan (Dato-DXd) also demonstrated clinically meaningful efficacy outcomes. The triplet regimen of amivantamab combined with lazertinib and chemotherapy (SUCRA = 0.816) and ivonescimab combined with chemotherapy (SUCRA = 0.779) both exhibited capabilities in prolonging PFS, though the triplet regimen was associated with the highest incidence of severe-grade AEs compared to all other treatment options.

Addressing Unmet Needs in Advanced EGFR-Mutated NSCLC

Despite meaningful advances with EGFR-targeted tyrosine kinase inhibitors, several patient populations with EGFR-mutated NSCLC continue to face significant therapeutic gaps. The literature from the past three years highlights a convergence of unmet needs spanning acquired resistance, rare mutation subtypes, CNS involvement, and the post-TKI treatment landscape.

• Post-TKI resistance and the C797S mutation barrier. Resistance to third-generation EGFR-TKIs, particularly osimertinib, is driven by on-target mutations such as C797S, off-target mechanisms including MET amplification, and histologic transformations such as epithelial-to-mesenchymal transition. Fourth-generation EGFR-TKIs (e.g., BI4020, BI-4732) are in early clinical development to address C797S-mediated resistance, with BI-4732 demonstrating activity across EGFR-activating mutations (E19del, L858R), T790M, and C797S in patient-derived preclinical models, including intracranial models. However, no approved targeted options currently exist for patients progressing on osimertinib.

• EGFR exon 20 insertion mutations. This subgroup, representing up to 10% of all EGFR mutations, remains difficult to treat. Approved exon 20 insertion-specific inhibitors yield variable outcomes, and the insertion location (near-loop vs. far-loop) differentially impacts TKI sensitivity. In the ZENITH20 trial (n = 115), poziotinib achieved an ORR of 14.8% in the overall cohort, failing its primary endpoint, though exploratory analysis showed superior benefit in near-loop insertions (PFS 11.1 vs. 3.5 months; p = 0.016). Osimertinib at 80 mg once daily showed limited efficacy in a phase II Korean multicenter study (n = 15), with a median PFS of 3.8 months and median OS of 6.5 months, predominantly achieving disease stabilization rather than objective response.

• CNS metastases in EGFR-mutant lung adenocarcinoma. Patients with brain metastases represent a high-risk population with limited intracranial control on TKI monotherapy. A retrospective analysis (n = 69) demonstrated that adding intracranial radiotherapy to osimertinib significantly improved 3-year intracranial local control (77% vs. 23%; p < 0.01) and intracranial distant control (23.2 vs. 8.7 months; p < 0.01), though no OS benefit was observed. The presence of T790M mutation was independently associated with improved intracranial local control. Drugs with strong CNS penetration remain an active area of need, as illustrated by a case report of EGFR S768I/V769L compound mutation in which intracranial progression ultimately drove mortality despite systemic disease control.

• Post-TKI systemic therapy: the role of ADCs. For patients who have exhausted EGFR-TKI options, antibody-drug conjugates (ADCs) are emerging as a key therapeutic strategy. A meta-analysis of nine studies (n = 1,092) reported a pooled ORR of 44.7% (95% CI 36.7%–52.9%) for ADCs in EGFR-mutant NSCLC after TKI failure, with TROP2-targeting ADCs achieving a significantly higher ORR (50.6%; 95% CI 40.3%–60.9%) than HER3-targeting ADCs (34.2%; 95% CI 28.8%–39.8%) (P for interaction = 0.006). Among RCTs, sacituzumab tirumotecan demonstrated improvement in both PFS (pooled HR 0.40; 95% CI 0.25–0.64) and OS (pooled HR 0.57; 95% CI 0.44–0.76) versus chemotherapy, while patritumab deruxtecan improved PFS (HR 0.77; 95% CI 0.63–0.94; P = 0.011) without mature OS data. Biomarker-guided patient selection remains an unresolved challenge across ADC development.

• Low-level MET amplification as a resistance driver. MET amplification is an established mechanism of acquired EGFR-TKI resistance, but the clinical relevance of low gene copy number (GCN) MET amplification is poorly defined. A case report documented a 7-month PFS with salvage savolitinib plus osimertinib in a patient with acquired MET amplification at GCN 3, suggesting potential benefit even below conventional high-level amplification thresholds, though confirmation in larger cohorts is needed.

Dual PD-1/VEGF Inhibition: A Novel Approach in NSCLC

Research into EGFR-mutant NSCLC has moved well beyond TKI monotherapy, with antibody-drug conjugates (ADCs) emerging as one of the most clinically advanced therapeutic strategies in the post-TKI resistance setting. A 2026 meta-analysis encompassing 1,092 patients across nine studies reported a pooled objective response rate (ORR) of 44.7% (95% CI 36.7%–52.9%) for ADCs in this population, with efficacy proving target- and drug-specific rather than a uniform class effect. TROP2-targeting ADCs achieved a pooled ORR of 50.6% (95% CI 40.3%–60.9%), significantly outperforming HER3-targeting ADCs at 34.2% (95% CI 28.8%–39.8%) (P for interaction = 0.006). Sacituzumab tirumotecan (Sac-TMT), a TROP2-directed ADC, demonstrated pooled hazard ratios of 0.40 (95% CI 0.25–0.64) for PFS and 0.57 (95% CI 0.44–0.76) for OS versus chemotherapy across two RCTs — the only agent in this class to show improvement in both endpoints. The HER3-directed ADC patritumab deruxtecan (HER3-DXd) improved PFS in the phase III HERTHENA-Lung02 trial (HR 0.77; 95% CI 0.63–0.94; P = 0.011), though OS data remained immature at the time of analysis. Across studies, median PFS ranged from 5.5 to 11.1 months, with mature median OS data available from only three studies (range 11.9–16.2 months).

Alongside ADCs, the c-MET pathway has attracted significant attention as a therapeutic target, particularly given its role in EGFR TKI resistance. Telisotuzumab vedotin (TV-t, Emrelis), a first-in-class c-MET-directed ADC, demonstrated a 34.6% ORR in c-MET-high patients in the pivotal LUMINOSITY phase II trial, with a median overall survival of 14.5 months and median PFS of 5.7 months in this subgroup. In phase Ib combination studies, TV-t paired with osimertinib achieved a 50% ORR and 7.4-month PFS, underscoring the potential of targeting c-MET amplification — a recognised bypass resistance mechanism — in combination with third-generation EGFR TKIs. The AXL receptor tyrosine kinase represents another bypass resistance mechanism under active investigation; preclinical data indicate that AXL inhibitors including glesatinib, sitravatinib, and BGB-324, in combination with erlotinib, significantly inhibit growth of erlotinib-resistant NSCLC cells through induction of G2-M cell cycle arrest and enhanced apoptosis, while also reducing migration and epithelial-to-mesenchymal transition.

At the molecular level, fourth-generation EGFR TKIs are being developed specifically to address the C797S tertiary mutation — a primary driver of resistance to third-generation agents such as osimertinib — which arises in the context of EGFR double mutations (19Del/C797S or L858R/C797S) and triple mutations (19Del/T790M/C797S or L858R/T790M/C797S). A key strategy involves targeting the catalytic Lys745 residue using covalent warheads such as sulfonyl fluoride, phosphine oxides, and esters, as well as non-covalent analogues that offer reduced off-target effects. Hybrid scaffolds combining pharmacophoric features from osimertinib and brigatinib with Lys745-targeting warheads have been highlighted as a promising design direction. Beyond direct EGFR targeting, the PI3K/AKT signalling axis — activated independently of EGFR mutation status via mediators such as PAK1 and SGK1 — continues to be explored as a co-target, with preclinical evidence suggesting that combined inhibition of PI3K/AKT and SGK1 produces synergistic anticancer activity through modulation of mTORC1, Ras/MEK/ERK, and Wnt/β-catenin signalling pathways.

Ivonescimab's Place in a Crowded NSCLC Landscape

The standard of care for EGFR-mutant NSCLC has been anchored by third-generation EGFR tyrosine kinase inhibitors (TKIs), with osimertinib demonstrating superior progression-free survival (PFS) and overall survival (OS) compared to earlier-generation TKIs in the frontline setting, though median OS remains approximately three years in pivotal trials. In a retrospective study of 229 patients receiving first-line osimertinib, the objective response rate was 71%, median PFS was 23.3 months (95% CI: 19.6–26.7), and median OS was 33.7 months (95% CI: 31.3–58.6). Mutation subtype further modulated outcomes: the EGFR exon 21 L858R point mutation (hazard ratio [HR] = 1.56, 95% CI: 1.04–2.34, p = 0.0328) and liver metastasis (HR = 2.63, 95% CI: 1.53–4.49, p = 0.0004) were significant predictors of shorter PFS. Lazertinib, another third-generation EGFR TKI, has also demonstrated competitive efficacy in this space. A meta-analysis of three randomized controlled trials showed a pooled PFS hazard ratio of 0.44 (95% CI: 0.37–0.53) favoring lazertinib over first-generation EGFR TKIs, though OS differences were not statistically significant (HR: 0.82, 95% CI: 0.64–1.06). In a real-world cohort of 103 patients with acquired EGFR T790M mutation, lazertinib achieved an objective response rate of 72.8%, with PFS rates of 81.7% at 6 months and 65.1% at 12 months.

Investigational strategies targeting resistance mechanisms following osimertinib progression have shown meaningful, if context-specific, clinical benefit. In the ORCHARD study, osimertinib plus savolitinib — targeting MET amplification as a resistance driver — yielded a confirmed objective response rate of 47% (80% CI: 35–60), a median duration of response of 14.5 months (95% CI: 5.6–18.7), a median PFS of 7.6 months (95% CI: 3.2–15.9), and a median OS of 20.7 months (95% CI: 9.9–34.8) in 32 patients with MET-amplified EGFR-mutant NSCLC. For acquired BRAF V600E-mediated resistance, a case series (n=12) evaluating triplet therapy with osimertinib, dabrafenib, and trametinib reported a median PFS of 7 months, a median OS of 46.2 months, and a 60% partial response rate on first post-treatment scan. Preclinical data further support the combination of amivantamab (EGFR-MET bispecific antibody) and patritumab deruxtecan (HER3 antibody-drug conjugate) in osimertinib-resistant cell lines, where synergistic effects were observed in vitro and the combination polarized macrophages toward the M1 phenotype in vivo, though clinical validation remains pending.

Upfront intensification strategies and CNS-directed approaches represent additional dimensions of the evolving treatment landscape. The FLAURA-2 trial has been cited as an example of combining EGFR TKIs with chemotherapy to extend disease control, while local therapy (LT) added to third-generation EGFR TKIs in symptomatic brain metastasis patients was associated with significantly longer OS compared to TKIs alone (43 vs. 28 months; HR 0.36, 95% CI: 0.17–0.77; p = 0.011), with the benefit particularly pronounced in oligo-brain metastasis patients (43 vs. 31 months; HR 0.22; 95% CI: 0.05–0.92; p = 0.015). For CNS-specific efficacy, osimertinib 160 mg in T790M-positive patients with brain metastases achieved an intracranial objective response rate of 55.0% and a median PFS of 7.6 months (95% CI: 5.0–16.6), while the ASTRIS Korean subset demonstrated a CNS objective response rate of 62.5% (95% CI: 38.3–82.6%) and a median intracranial PFS of 13.0 months (95% CI: 7.21–18.8) with osimertinib 80 mg. Across these data, the trajectory is clear: while osimertinib-based regimens remain the backbone of frontline therapy, the field is actively defining optimal sequencing and combination strategies to address the inevitability of acquired resistance.

Ivonescimab's FDA Test: A Bellwether for Bispecifics in NSCLC

The journey of ivonescimab, a novel bispecific antibody targeting both PD-1 and VEGF, towards a potential FDA approval for EGFR-mutated non-small cell lung cancer (NSCLC) after TKI progression is a high-stakes event for Summit Therapeutics and Akeso. This drug offers a promising new avenue for patients facing limited options, with studies indicating its combination regimens can achieve significant objective response rates and progression-free survival in this challenging population. The dual mechanism of action, modulating the tumor immune microenvironment, represents a scientific advancement in oncology.

However, the path to U.S. market entry is fraught with regulatory complexities. The FDA has increasingly scrutinized oncology drug approvals, particularly those relying on surrogate endpoints or exploratory data without a clear overall survival (OS) benefit. This shift is informed by past experiences where drugs granted accelerated approval were later withdrawn due to failure to confirm OS, leading to substantial healthcare costs without proven long-term patient benefit. For ivonescimab, the initial lack of a clear OS benefit in its primary analysis, despite promising PFS, places it directly under this heightened regulatory microscope.

Key considerations for the drug's future include:

• The FDA's Bar for OS: The agency's insistence on robust OS data means that even with strong PFS and ORR, the absence of a definitive OS signal could be a significant hurdle for approval or conversion from accelerated to regular approval.

• Competitive Differentiation: The landscape for EGFR-mutated NSCLC post-TKI is becoming crowded. While ivonescimab has shown efficacy, other regimens, such as amivantamab plus lazertinib plus chemotherapy, have also demonstrated strong PFS benefits. Ivonescimab will need to clearly articulate its unique value proposition, whether through superior efficacy, a distinct safety profile, or specific patient subgroups.

• Safety Profile Management: While generally manageable, the increased risk of adverse events associated with AK112-based regimens, as noted in meta-analyses, will require careful monitoring and management in clinical practice to ensure patient tolerability and sustained treatment.

Ultimately, the FDA's decision will not only determine ivonescimab's fate but also send a strong signal regarding the agency's expectations for novel oncology therapies, particularly bispecific antibodies and those with initial data from ex-U.S. studies, in demonstrating unequivocal clinical benefit.